Global Blood Therapeutics, Inc. (GBT)
(Delayed Data from NSDQ)
$55.18 USD
+1.34 (2.49%)
Updated May 3, 2019 04:00 PM ET
After-Market: $55.12 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$55.18 USD
+1.34 (2.49%)
Updated May 3, 2019 04:00 PM ET
After-Market: $55.12 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
Global Blood Therapeutics (GBT) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Global Blood (GBT) delivered earnings and revenue surprises of -3.09% and 6.18%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
Global Blood Therapeutics (GBT) May Report Negative Earnings: Know the Trend Ahead of Q4 Release
by Zacks Equity Research
Global Blood (GBT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Global Blood's (GBT) MAA for Oxbryta Accepted in Europe
by Zacks Equity Research
Global Blood's (GBT) Marketing Authorization Application for the label expansion of Oxbryta tablets has been accepted by the European Medicines Agency.
New Strong Sell Stocks for January 6th
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today
New Strong Sell Stocks for December 15th
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today
Why Is Global Blood (GBT) Down 27.3% Since Last Earnings Report?
by Zacks Equity Research
Global Blood (GBT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Sanofi (SNY) Blood Disorder Candidate Gets FDA's Rejection
by Zacks Equity Research
The FDA gives a complete response letter to Sanofi's (SNY) regulatory application for sutimlimab for the treatment of hemolysis in adult patients with cold agglutinin disease.
Global Blood Therapeutics (GBT) Surges: Stock Moves 6.9% Higher
by Zacks Equity Research
Global Blood Therapeutics (GBT) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.
Global Blood (GBT) Q3 Loss Wider Than Expected, Sales Miss
by Zacks Equity Research
Global Blood (GBT) reports a wider-than-expected loss and misses sales estimates in the third quarter of 2020.
Global Blood Therapeutics (GBT) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
Global Blood (GBT) delivered earnings and revenue surprises of -34.72% and -17.26%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
GlycoMimetics' Rivipansel Gets Rare Pediatric Disease Status
by Zacks Equity Research
GlycoMimetics' (GLYC) rivipansel gets a Rare Pediatric Disease designation by the FDA for the treatment of SCD in patients 18 years old and younger.
Sanofi's Dupixent Gets Breakthrough Status for New Indication
by Zacks Equity Research
Sanofi's (SNY) blockbuster drug, Dupixent gets Breakthrough Therapy designation from the FDA as potential treatment for eosinophilic esophagitis.
Why Is Global Blood (GBT) Down 5.6% Since Last Earnings Report?
by Zacks Equity Research
Global Blood (GBT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Global Blood Therapeutics (GBT) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Global Blood (GBT) delivered earnings and revenue surprises of 27.12% and 67.11%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Top 7 Stocks Set to Beat on Earnings Today After Market
by Nalak Das
Seven top-ranked companies are poised to beat on earnings today after the closing bell.
Global Blood to Seek Approval of Oxbryta in Europe for SCD
by Zacks Equity Research
Global Blood (GBT) plans to seek approval for Oxbryta tablets to treat hemolytic anemia in SCD patients aged 12 years and older in Europe.
Global Blood Seeks Label Expansion of Oxbryta in Kids With SCD
by Zacks Equity Research
Global Blood (GBT) seeks label expansion of Oxbryta for the treatment of SCD in children aged 4 to 11 years.
Global Blood (GBT) Down 16.3% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Global Blood (GBT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
How Global Blood Therapeutics (GBT) Stock Stands Out in a Strong Industry
by Zacks Equity Research
Global Blood Therapeutics (GBT) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Sanofi's Blood Disorder Candidate Gets FDA's Priority Review
by Zacks Equity Research
The FDA grants priority review to Sanofi's (SNY) regulatory application for sutimlimab for the treatment of hemolysis in adult patients with cold agglutinin disease (CAD).
Global Blood Therapeutics (GBT) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Global Blood (GBT) delivered earnings and revenue surprises of 18.37% and 268.91%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Should You Global Blood (GBT) Ahead of Earnings?
by Zacks Equity Research
Global Blood (GBT) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Why Is Global Blood (GBT) Down 15% Since Last Earnings Report?
by Zacks Equity Research
Global Blood (GBT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Global Blood (GBT) Q4 Earnings Miss, Voxelotor Gets FDA Nod
by Zacks Equity Research
Global Blood (GBT) reports wider-than-expected loss in the fourth quarter of 2019. The FDA approves voxelotor (Oxbryta) for the treatment of SCD in adults, and children 12 years of age and older.
Global Blood Therapeutics (GBT) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Global Blood (GBT) delivered earnings and revenue surprises of -41.80% and 311.72%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?